This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) (NCT05722015), a randomized phase 3 study. The primary outcome is Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT05722015 |
| Phase | Phase 3 |
| Condition | Metastatic Non-small Cell Lung Cancer |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None (open label) |
| Enrollment | 377 |
| Arms in the primary outcome | 2 |
| Lead sponsor | Merck Sharp & Dohme LLC |
| Results posted | Yes |
2. Clinical Question
Population
Adults with treatment-naïve metastatic non-small cell lung cancer (NSCLC) receiving first-line treatment. The primary pharmacokinetic analysis population was narrower: randomized participants who received a Cycle 1 dose, had at least one valid postdose pharmacokinetic sample in Cycle 1, and had a model-based AUC assessment available.
Intervention
Subcutaneous pembrolizumab formulated with berahyaluronidase alfa, administered with platinum doublet chemotherapy. The described regimen gives 790 mg on Day 1 of each 6-week cycle for 18 cycles, up to approximately 108 weeks.
Comparator
Intravenous pembrolizumab administered with platinum doublet chemotherapy. The arm description gives a 400 mg pembrolizumab infusion; the registry record does not report a corresponding treatment duration in the arm description.
Primary question
Does subcutaneous pembrolizumab formulated with berahyaluronidase alfa produce pembrolizumab exposure, measured by AUC from time 0 to 6 weeks after the first dose, that meets the study’s noninferiority objective compared with intravenous pembrolizumab?
The trial focuses its primary comparison on pharmacokinetics, not on a primary clinical efficacy endpoint. AUC from time 0 to 6 weeks represents drug exposure over the first treatment cycle. The registry describes the primary hypotheses as noninferiority of the subcutaneous formulation with respect to pharmacokinetic parameters. The formal noninferiority margin and the detailed decision rule are not reported in the registry record, so the result cannot be independently assessed against that threshold from the record alone.
The trial also lists safety, anti-drug antibodies, objective response rate, progression-free survival, and overall survival among its secondary outcomes. Their inclusion gives the study a broader set of descriptive and clinical questions, but the posted primary result is specifically about first-dose AUC. These different outcomes measure distinct aspects of treatment and should not be treated as interchangeable evidence.
3. Trial Design
This is a phase 3, randomized, open-label, parallel-group clinical study in adults with metastatic NSCLC. The registry record lists enrollment of 377 and describes the setting as first-line treatment. Participants were assigned to one of two treatment groups: subcutaneous pembrolizumab formulated with berahyaluronidase alfa plus platinum doublet chemotherapy, or intravenous pembrolizumab plus platinum doublet chemotherapy. Masking is listed as none.
The subcutaneous arm description specifies 790 mg on Day 1 of each 6-week cycle for 18 cycles, up to approximately 108 weeks. The intravenous arm description specifies a 400 mg infusion with platinum doublet chemotherapy. The registry lists pemetrexed, cisplatin, carboplatin, paclitaxel, nab-paclitaxel, and filgrastim among the interventions. Which chemotherapy choices were used for individual participants, and how those choices were assigned, are not reported in the registry record.
The primary endpoint is a pharmacokinetic measure collected during Cycle 1. For the subcutaneous arm, the stated sampling schedule includes predose and postdose measurements on Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42. For the intravenous arm, it includes predose, end of infusion, and measurements on Days 4, 15, 29, and 42. Cycle length is stated as 42 days. These schedules describe the planned collection timepoints, while the primary analysis population requires usable postdose pharmacokinetic data and a model-based AUC assessment.
The record lists a study start date of 2023-02-14, a primary completion date of 2024-07-12, and an overall status of active, not recruiting. The sample-size justification, randomization procedure, details of allocation concealment, protocol deviations, and any interim analyses are not reported in the registry record. The posted enrollment and arm analysis counts describe different stages or populations and should not be assumed to be identical.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: All randomized participants.
Overall Study
| Stage | Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy | Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy |
|---|---|---|
| STARTED | 251 | 126 |
| COMPLETED | 0 | 0 |
| NOT COMPLETED | 251 | 126 |
Reasons for not completing this period:
| Reason | Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy | Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy |
|---|---|---|
| Death | 57 | 37 |
| Lost to Follow-up | 1 | 0 |
| Withdrawal by Subject | 5 | 1 |
| Participants Ongoing | 188 | 88 |
Analysis population for the primary outcome, as defined in the registry: All randomized participants who received a dose in Cycle 1 with at least 1 valid postdose pharmacokinetic (PK) sample available in Cycle 1 and for whom a model-based assessment of AUC0-6 weeks could be made.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
Population: All randomized participants.
| Characteristic | Unit | Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy | Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy | Total |
|---|---|---|---|---|
| Participants analysed | 251 | 126 | 377 | |
| Age, Continuous | Years | 64.7 (SD 9.6) | 64.8 (SD 8.5) | 64.8 (SD 9.2) |
| Sex: Female, Male: Female | Participants | 69 | 40 | 109 |
| Sex: Female, Male: Male | Participants | 182 | 86 | 268 |
| Ethnicity (NIH/OMB): Hispanic or Latino | Participants | 74 | 41 | 115 |
| Ethnicity (NIH/OMB): Not Hispanic or Latino | Participants | 177 | 85 | 262 |
| Ethnicity (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 2 | 4 | 6 |
| Race (NIH/OMB): Asian | Participants | 74 | 36 | 110 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): Black or African American | Participants | 5 | 5 | 10 |
| Race (NIH/OMB): White | Participants | 158 | 78 | 236 |
| Race (NIH/OMB): More than one race | Participants | 12 | 3 | 15 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 |
6. Primary Endpoint
The registry lists the primary outcome as Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose, measured over Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days).
| Element | Registry entry |
|---|---|
| Result type | Geometric Mean |
| Measure of spread | Geometric Coefficient of Variation |
| Unit | μg·day/mL |
| Endpoint classification | not reduced to a single comparison |
The primary endpoint is pembrolizumab area under the serum concentration-time curve from time 0 to 6 weeks after the first dose, reported in μg·day/mL. The registry defines AUC0-6 weeks as a measure of drug exposure calculated from serum drug concentration over time during the first 6 weeks. Samples collected at prespecified timepoints were used to estimate this measure. The reported endpoint is the geometric mean AUC for each arm.
AUC is used because it summarizes exposure across a time interval rather than relying on a single concentration measurement. In general, pharmacokinetic measures such as AUC can help compare the extent of exposure under different administration routes. A first-cycle AUC comparison is not itself a measure of tumor response, disease progression, survival, or patient experience.
The primary population includes randomized participants who received a Cycle 1 dose, had at least one valid postdose pharmacokinetic sample in Cycle 1, and for whom a model-based assessment could be made. Thus, the estimate is based on participants with evaluable pharmacokinetic information, rather than necessarily every randomized participant. The number of participants reported for each arm’s primary result is 245 in the subcutaneous arm and 126 in the intravenous arm.
The registry reports geometric coefficient of variation as the dispersion measure alongside the geometric means. In general, this describes relative variability on a multiplicative scale and complements the central estimate. The record’s formal noninferiority margin and detailed model specifications are not reported in the registry record.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The posted primary results report a geometric mean AUC0-6 weeks of 1633 μg·day/mL in the subcutaneous pembrolizumab arm and 1438 μg·day/mL in the intravenous pembrolizumab arm. The corresponding geometric coefficients of variation are 40.41 and 26.23. These summaries describe the observed exposure distributions in the pharmacokinetic analysis populations; they do not by themselves establish a clinical benefit or a difference in clinical outcomes.
The reported geometric mean ratio is 1.14, with a 96% confidence interval from 1.06 to 1.22 and p < 0.001. The registry labels this analysis as noninferiority and reports Welch’s t test as the method. The record does not state the ratio convention or the noninferiority margin. Therefore, the ratio and interval should be interpreted as the registry’s reported comparison, without assuming a particular margin or reconstructing the exact decision rule.
In general, a confidence interval represents a range of values compatible with the data and the analysis assumptions at its stated confidence level. It communicates uncertainty around an estimate; it is not a range containing a specified proportion of individual participants’ values. Here the interval is reported at 96%. The p-value describes the result under the tested statistical model and null hypothesis, but the exact hypothesis and its relationship to the noninferiority margin are not detailed in the registry record. A small p-value alone does not supply the missing margin or establish the clinical importance of the exposure estimate.
The trial’s primary question is pharmacokinetic. Although objective response rate, progression-free survival, and overall survival are listed as secondary outcomes, their presence in the outcome list does not make the AUC result evidence about those outcomes. The registry record lists 16 outcome measures and 2 analyses, but it does not provide a complete multiplicity strategy or full results for every listed measure in the registry record. Claims about efficacy or comparative safety therefore require outcome-specific results and their analysis context.
The primary analysis population requires valid postdose pharmacokinetic data and an estimable model-based AUC. The arm counts for that endpoint are 245 and 126. They are not interchangeable with the registry’s enrollment figure of 377, and the record does not provide a complete account of why participants are not represented in the primary analysis population. This matters because an evaluable pharmacokinetic subset may differ from the full randomized population. The reported estimate should be understood in the population that the registry defines, rather than automatically generalized to every randomized participant.
Overall, the posted data provide a comparison of first-dose exposure under the two administration approaches and a reported noninferiority analysis. They do not, without the margin and fuller protocol-level details, allow readers to independently verify the formal noninferiority criterion. They also do not answer whether clinical outcomes differ, or whether all secondary outcomes support a consistent conclusion.
9. Statistical Methods Explained
What does the geometric mean describe?
The primary endpoint is reported as a geometric mean, a summary suited to measurements that are interpreted on a multiplicative scale. In general, the geometric mean is obtained by transforming values to a logarithmic scale, averaging there, and transforming back. It is not the same summary as an arithmetic mean. The registry reports geometric coefficient of variation alongside each arm’s estimate to describe relative spread. Such spread is useful because pharmacokinetic measurements can vary proportionally rather than by a fixed additive amount.
The reported geometric mean AUC values are 1633 for the subcutaneous formulation and 1438 for intravenous pembrolizumab, in μg·day/mL. Their reported geometric coefficients of variation are 40.41 and 26.23. These are arm-level summaries; they do not show each participant’s measurements or explain the shape of the underlying distributions. The registry record does not report the full concentration data, the model specification used to estimate AUC, or diagnostic checks for that model.
What does a geometric mean ratio mean?
A geometric mean ratio expresses a comparison of geometric means on a relative scale. A value of 1 would represent equal values under the stated ratio convention. The registry reports a ratio of 1.14 and a 96% confidence interval from 1.06 to 1.22. The ratio orientation and detailed calculation are not reported in the registry record, so the reported value should be quoted as the registry’s comparison rather than assigned an unstated numerator or denominator. The interval communicates uncertainty in that relative estimate under the analysis assumptions; it does not describe the range of individual AUC values.
Why use a confidence interval?
In general, a confidence interval combines an estimate with information about its precision. A narrower interval indicates greater precision under the model and sampling assumptions than a wider interval, while an interval’s location indicates which values remain compatible with the data. The 96% interval is a statistical interval for the reported comparison, not a guarantee that the true effect lies within it. Its interpretation depends on the sampling model, the analysis population, and the method used to construct it.
What is the reported test?
The registry identifies Welch’s t test for the reported comparison and labels the analysis as noninferiority. In general, Welch’s t test compares means while allowing the groups to have different variances; it is often used when equal variance is not assumed. The registry does not describe the transformation, exact test statistic, degrees of freedom, or how the test was adapted to the geometric mean ratio. The method label alone is therefore not enough to reconstruct every analytical step.
The reported p-value is p < 0.001. In general, a p-value measures how incompatible the observed data are with a specified null hypothesis under the assumed model. It is not the probability that the null hypothesis is true, and it does not measure the size or clinical importance of an effect. The registry record does not give the full null hypothesis, the noninferiority margin, or the exact decision rule. Consequently, the p-value should be read with the reported interval and the registry’s noninferiority label, not as a standalone demonstration that a particular prespecified criterion was met.
Why does a noninferiority margin matter?
In general, a noninferiority analysis asks whether the uncertainty around a comparative estimate excludes differences that would be considered unacceptably unfavorable according to a prespecified margin. That margin is central to the interpretation: an interval can be judged against it only when its value, direction, and analysis convention are known. The registry record does not report the margin or sufficient detail to reconstruct the rule. The label “noninferiority” identifies the study objective, but the posted summary alone does not permit an independent check against the protocol criterion.
How should unequal variability be understood?
In general, over-dispersion or unequal variability means that observations vary more than a simple model expects, or that variability differs across groups. Ignoring this can make standard errors and confidence intervals unreliable. Welch’s method is designed to avoid requiring equal group variances when comparing arithmetic means, but the registry does not explain how its test was applied to this geometric-mean-ratio analysis. The geometric coefficients of variation convey relative spread in each arm, but they do not by themselves establish whether the analysis model was adequate.
What does the analysis population represent?
The primary pharmacokinetic population consists of randomized participants who received a Cycle 1 dose, had at least one valid postdose pharmacokinetic sample during that cycle, and had a model-based AUC assessment available. In general, excluding participants without an estimable endpoint can affect representativeness if endpoint availability is related to treatment, health status, or other factors. The registry record does not report the reasons for missing or unevaluable pharmacokinetic data, or analyses examining their possible impact.
How do planning illustrations differ from observed results?
In general, sample-size planning illustrations based on an observed effect are hypothetical design calculations, not evidence about the power achieved by the completed trial. Their results depend on assumptions such as significance level, allocation, and the fraction of an effect used for planning. The registry record does not report the trial’s own sample-size justification or detailed planning assumptions. Any planning illustration should therefore be distinguished from the observed arm counts and the reported analysis, and should not be described as observed power.
10. Analyses Reported by the Sponsor
| Method | Estimate | 95% CI | P-value |
|---|---|---|---|
| Welch's t test | Geometric Mean Ratio (GMR) 1.14 | 1.06 to 1.22 | < 0.001 |
The registry reports the sponsor’s primary comparison as a noninferiority analysis using Welch’s t test. The reported geometric mean ratio is 1.14, its 96% confidence interval is 1.06 to 1.22, and the reported p-value is p < 0.001. These are the results to use when describing the registry’s own analysis.
The posted arm summaries include geometric mean AUC values of 1633 and 1438, with geometric coefficients of variation of 40.41 and 26.23, for the subcutaneous and intravenous arms respectively. A separate recalculated estimate from summary statistics is not reported in the registry record. The record identifies no discrepancy between the sponsor analysis and a recalculation, but the absence of a reported discrepancy does not add methodological detail or reveal the formal noninferiority margin.
In general, an unadjusted recalculation from summary statistics can be useful as a check on a reported comparison, but it may not reproduce an analysis that uses different modeling choices, data handling, or covariate adjustment. Where an actual discrepancy is identified, the sponsor’s own analysis takes precedence in reporting the trial result. Here, the registry’s sponsor analysis is the reported inferential result; it should not be supplemented with an unreported alternative estimate or treated as a substitute for protocol details that are absent from the record.
11. Multiplicity, Missing Data and Analysis Populations
The registry lists 16 outcome measures and 2 analyses. The primary endpoint is Cycle 1 AUC0-6 weeks, while secondary outcomes include other pharmacokinetic measures, anti-drug antibodies, objective response rate, progression-free survival, and overall survival. These outcomes address different questions and may involve multiple statistical comparisons. The number of listed outcomes alone does not reveal which were formally tested, which were descriptive, or how any testing sequence was organized.
The multiplicity strategy, including any adjustment for multiple endpoints or analyses, is not reported in the registry record. The registry also does not report a complete statistical analysis plan, interim analyses, or the planned hierarchy of hypotheses. Without those details, the p-value for the primary analysis should not be interpreted as if it were necessarily adjusted for every listed outcome, and secondary findings should not be treated as confirmatory solely because they appear in the outcome list.
The primary pharmacokinetic population requires participants to have received a dose, have at least one valid postdose sample in Cycle 1, and have an estimable model-based AUC. The arm counts reported for that endpoint are 245 and 126. Reasons for missing samples or non-estimable AUC values, missing-data methods, sensitivity analyses, and comparisons between included and excluded randomized participants are not reported in the registry record.
For the clinical outcomes listed as secondary, the registry entries described in the registry record do not provide the full results, analysis populations, censoring rules, or missing-data procedures. Those details matter because a result can depend on how follow-up and incomplete observations are handled. The registry’s primary pharmacokinetic result should therefore be kept separate from any conclusion about secondary clinical outcomes, and absence of a reported method should not be filled in by assumption.
12. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy | 98 | 251 | 39.0% |
| Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy | 51 | 126 | 40.5% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy | 61 of 251 |
| Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy | 37 of 126 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 5% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy | 236 of 251 |
| Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy | 123 of 126 |
Most frequent serious adverse event terms
| Event term | Organ system | Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy | Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy |
|---|---|---|---|
| Pneumonia | Infections and infestations | 25 of 251 | 13 of 126 |
| Thrombocytopenia | Blood and lymphatic system disorders | 10 of 251 | 3 of 126 |
| Febrile neutropenia | Blood and lymphatic system disorders | 10 of 251 | 2 of 126 |
| Anaemia | Blood and lymphatic system disorders | 3 of 251 | 6 of 126 |
| Neutropenia | Blood and lymphatic system disorders | 7 of 251 | 2 of 126 |
| Death | General disorders | 4 of 251 | 1 of 126 |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | 2 of 251 | 3 of 126 |
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | 3 of 251 | 1 of 126 |
| Atrial fibrillation | Cardiac disorders | 2 of 251 | 1 of 126 |
| Adrenal insufficiency | Endocrine disorders | 1 of 251 | 2 of 126 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy | Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy |
|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | 146 of 251 | 85 of 126 |
| Neutropenia | Blood and lymphatic system disorders | 105 of 251 | 40 of 126 |
| Leukopenia | Blood and lymphatic system disorders | 74 of 251 | 33 of 126 |
| Thrombocytopenia | Blood and lymphatic system disorders | 71 of 251 | 35 of 126 |
| Nausea | Gastrointestinal disorders | 63 of 251 | 30 of 126 |
| Aspartate aminotransferase increased | Investigations | 47 of 251 | 18 of 126 |
| Alanine aminotransferase increased | Investigations | 44 of 251 | 18 of 126 |
| Constipation | Gastrointestinal disorders | 35 of 251 | 23 of 126 |
| Fatigue | General disorders | 40 of 251 | 17 of 126 |
| Decreased appetite | Metabolism and nutrition disorders | 28 of 251 | 27 of 126 |
Serious events with the highest arm-level rate: pneumonia (10.3%), anaemia (4.8%), febrile neutropenia (4.0%), thrombocytopenia (4.0%), neutropenia (2.8%).
The registry reports serious adverse events among 98 of 251 participants at risk in the subcutaneous pembrolizumab arm and 51 of 126 participants at risk in the intravenous pembrolizumab arm. It also reports other adverse events among 236 of 251 and 123 of 126 participants at risk, respectively. These are participant counts, not counts of individual event episodes. The record reports deaths of 61 and 37 in the two arms.
The most frequent serious adverse event terms listed are pneumonia (10.3%), anaemia (4.8%), febrile neutropenia (4.0%), thrombocytopenia (4.0%), neutropenia (2.8%), and pulmonary embolism (2.4%). These percentages are reported as given; the registry entries do not provide the event-specific denominators or a complete account of event timing. The terms should not be read as a ranking of all possible harms or as a causal assessment.
In general, adverse-event counts require context about the definition, observation period, severity, relatedness assessment, and the number of participants followed. Those details, as well as the causes of deaths and comparative statistical analyses for safety, are not reported in the registry record. The counts alone do not establish that one treatment caused an event or that the event risk differs between groups.
13. What the Result Does, and Does Not, Mean
The central posted result is a comparison of first-dose pembrolizumab exposure over the first 6 weeks. The registry reports geometric mean AUC values of 1633 μg·day/mL for subcutaneous pembrolizumab formulated with berahyaluronidase alfa and 1438 μg·day/mL for intravenous pembrolizumab. It reports a geometric mean ratio of 1.14, a 96% confidence interval of 1.06 to 1.22, and p < 0.001, with the analysis labeled noninferiority.
These results describe pharmacokinetic exposure in the endpoint-specific analysis population. They do not, on their own, establish whether tumor response, progression-free survival, overall survival, quality of life, or other patient outcomes differ. Those outcomes are listed as secondary measures, but their presence does not make them conclusions of the primary AUC analysis.
The result also does not independently verify the formal noninferiority criterion. A noninferiority margin and full decision rule are not reported in the registry record. Without them, readers can report the stated analysis and its uncertainty, but cannot check whether the confidence interval meets the exact prespecified threshold. The registry’s label for the analysis is important context, but it does not replace the missing criterion.
Likewise, the reported safety counts are descriptive unless accompanied by fuller definitions, follow-up details, and comparative analyses. Counts of participants with serious or other adverse events and deaths do not alone establish causation or a difference between treatment groups. They should be interpreted in relation to the respective at-risk populations and the unreported details of safety ascertainment.
In general, the distinction between a pharmacokinetic endpoint and clinical outcomes is fundamental: drug exposure is a measure of how much drug is present over time, while clinical outcomes address what happens to participants. The posted data support describing the exposure comparison and its reported precision. They do not justify a broader claim about treatment effectiveness or safety.
14. Why This Trial Matters Statistically
This study is statistically notable because its primary comparison concerns drug exposure after two different administration routes, while both arms receive platinum doublet chemotherapy. The endpoint is a first-cycle AUC measure, summarized by geometric means and compared through a geometric mean ratio. This makes the interpretation dependent not only on the central estimates, but also on the variability, analysis population, model, confidence interval, and noninferiority criterion.
The registry reports a noninferiority objective, a ratio estimate, a 96% confidence interval, and a p-value. Reading these together illustrates why a hypothesis label and a small p-value do not answer every statistical question. A noninferiority margin determines how the interval is judged, yet that margin is not reported in the registry record. The result can therefore be accurately described while its formal criterion remains unavailable for independent review.
The defined pharmacokinetic analysis population also matters. Participants needed a dose, valid postdose sampling, and an estimable model-based endpoint. This is a principled endpoint-specific definition, but it means the reported comparison is not automatically a comparison of every randomized participant. Understanding the reasons for unavailable measurements and the treatment of missing data would help readers assess the robustness of the estimate.
Finally, the trial lists safety and clinical outcomes alongside pharmacokinetic outcomes. Keeping these outcome types separate prevents an exposure finding from being mistaken for evidence about response, progression, or survival. This is a useful case for distinguishing what a statistical estimate directly measures from the broader clinical questions that may motivate a study.
15. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The registry record does not report the noninferiority margin, ratio convention, complete statistical analysis plan, or details needed to reconstruct the exact test and decision rule. Although the primary analysis is labeled noninferiority and the result includes a confidence interval and p-value, the formal criterion cannot be independently checked from the reported information alone.
The analysis population is restricted to randomized participants who received a dose, had valid postdose pharmacokinetic data, and had an estimable model-based AUC. The registry record does not report the reasons for missing or unevaluable measurements, the number of randomized participants excluded from this analysis for each reason, or sensitivity analyses addressing missing data. This limits assessment of how representative the endpoint-specific population is of all randomized participants.
The two arm-level AUC summaries are accompanied by geometric coefficients of variation, but the concentration data, model specification, model diagnostics, and detailed uncertainty calculation are not reported in the registry record. The ratio orientation is also not stated. These omissions limit independent reproduction and detailed evaluation of the analysis.
The record lists multiple secondary outcomes but does not report a complete multiplicity strategy or the full results and methods for those outcomes in the registry record. Their testing status, analysis populations, follow-up rules, and missing-data methods are not reported in the registry record. The listed serious adverse event counts likewise lack complete information on definitions, timing, relatedness, and comparative inference.
The record describes a platinum doublet chemotherapy background and lists several chemotherapy drugs, but does not specify which chemotherapy regimens individual participants received. It also does not report the study’s own sample-size justification. These limitations do not invalidate the posted estimates, but they constrain how much can be inferred about the full protocol and how broadly the primary comparison can be interpreted.
16. Related Tutorials
17. Related Statistical Calculators
18. Sources
- ClinicalTrials.gov: A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) — NCT05722015.
- Registry record last updated 2026-08-26; status last verified 2026-07.
- Results first posted 2025-07-28.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
19. Record Summary
NCT05722015 is a phase 3 randomized, open-label, parallel-group study in adults with metastatic NSCLC receiving first-line treatment. It compares subcutaneous pembrolizumab formulated with berahyaluronidase alfa plus platinum doublet chemotherapy with intravenous pembrolizumab plus platinum doublet chemotherapy. Enrollment is listed as 377; the registry status is active, not recruiting.
The primary outcome is Cycle 1 AUC0-6 weeks after the first dose. The reported geometric mean AUC values are 1633 μg·day/mL and 1438 μg·day/mL. The reported geometric mean ratio is 1.14, with a 96% confidence interval of 1.06 to 1.22 and p < 0.001; the registry labels the analysis noninferiority.
Safety, immunogenicity, objective response rate, progression-free survival, and overall survival are listed as secondary outcomes. The registry record does not report the noninferiority margin, complete multiplicity strategy, sample-size justification, or full details needed to reconstruct the primary analysis.